Niche MRI developer InnerVision MRI of London, U.K., has received510(k) clearance for its Ortho 8000 0.14-tesla permanent magnetsystem. InnerVision has targeted the system at orthopedic, pediatric,and interventional uses (SCAN 8/30/95). Ortho 8000 will
Niche MRI developer InnerVision MRI of London, U.K., has received
510(k) clearance for its Ortho 8000 0.14-tesla permanent magnet
system. InnerVision has targeted the system at orthopedic, pediatric,
and interventional uses (SCAN 8/30/95). Ortho 8000 will be sold
in the U.S. by Vision Medical Services, and will be shown in Vision's
booth at next month's Radiological Society of North America meeting.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.